Reduced expression of miR-3653 in glioma and its correlations with clinical progression and patient survival.
Growing evidence in recent years have demonstrated that the dysregulation of microRNAs (miRNAs) strongly affected the biological development and progression of human tumors, including glioma. There have been few studies on the clinical significance of miRNAs in glioma. The aim of our study is to explore the expression pattern and the value of miR-3653 in the prognosis of glioma patients. qRT-PCR assays were performed to the miR-3653 expression level in 168 cases of glioma tissues and matched normal tissues. The correlations of miR-3653 expression level with the clinicopathological factors in glioma patients were analyzed. The associations between miR-3653 expression and survival of glioma patients were investigated by the Kaplan-Meier analysis and the log-rank test. The prognostic value of miR-3653 was estimated via univariate and multivariate analysis. We presented that miR-3653 level in glioma tissues is notably reduced compared to matched non-cancerous brain tissues (p<0.01). Clinical research revealed that the lower miR-3653 expression was associated with larger tumor size and lymph node metastasis, lower KPS (p=0.028), and advanced WHO grade (p=0.019). Moreover, the clinical data further suggested that the low expression of miR-3653 predicted a worse 5-year overall survival in glioma patients. Finally, the multivariate analysis confirmed that low miR-3653 expression (HR=2.682, 95% CI: 1.148-4.281, p=0.021) was a significant independent predictor of poor survival in glioma. Our findings suggested that miR-3653 could serve as a valuable prognostic indicator in glioma. Further researches are required to explore the potential function and mechanism of miR-3653 in glioma.